Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;182(5):1148-1157.
doi: 10.1111/bjd.18524. Epub 2019 Nov 27.

A risk prediction model for the development of subsequent primary melanoma in a population-based cohort

Affiliations

A risk prediction model for the development of subsequent primary melanoma in a population-based cohort

A E Cust et al. Br J Dermatol. 2020 May.

Abstract

Background: Guidelines for follow-up of patients with melanoma are based on limited evidence.

Objectives: To guide skin surveillance, we developed a risk prediction model for subsequent primary melanomas, using demographic, phenotypical, histopathological, sun exposure and genomic risk factors.

Methods: Using Cox regression frailty models, we analysed data for 2613 primary melanomas from 1266 patients recruited to the population-based Genes, Environment and Melanoma study in New South Wales, Australia, with a median of 14 years' follow-up via the cancer registry. Discrimination and calibration were assessed.

Results: The median time to diagnosis of a subsequent primary melanoma decreased with each new primary melanoma. The final model included 12 risk factors. Harrell's C-statistic was 0·73 [95% confidence interval (CI) 0·68-0·77], 0·65 (95% CI 0·62-0·68) and 0·65 (95% CI 0·61-0·69) for predicting second, third and fourth primary melanomas, respectively. The risk of a subsequent primary melanoma was 4·75 times higher (95% CI 3·87-5·82) for the highest vs. the lowest quintile of the risk score. The mean absolute risk of a subsequent primary melanoma within 5 years was 8·0 ± SD 4.1% after the first primary melanoma, and 46·8 ± 15·0% after the second, but varied substantially by risk score.

Conclusions: The risk of developing a subsequent primary melanoma varies considerably between individuals and is particularly high for those with two or more primary melanomas. The risk prediction model and its associated nomograms enable estimation of the absolute risk of subsequent primary melanoma, on the basis of on an individual's risk factors, and can be used to tailor surveillance intensity, communicate risk and provide patient education. What's already known about this topic? Current guidelines for the frequency and length of follow-up to detect new primary melanomas in patients with one or more previous primary melanomas are based on limited evidence. People with one or more primary melanomas have, on average, a higher risk of developing another primary invasive melanoma, compared with the general population, but an accurate way of estimating individual risk is needed. What does this study add? We provide a comprehensive risk prediction model for subsequent primary melanomas, using data from 1266 participants with melanoma (2613 primary melanomas), over a median 14 years' follow-up. The model includes 12 risk factors comprising demographic, phenotypical, histopathological and genomic factors, and sun exposure. It enables estimation of the absolute risk of subsequent primary melanomas, and can be used to tailor surveillance intensity, communicate individual risk and provide patient education.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: There are no conflicts of interest to declare.

Figures

Figure 1.
Figure 1.
Distribution of 1-year, 5-year and 10-year estimated absolute risks derived from the risk prediction model, for development of a second primary melanoma for people who have one previous melanoma (top row), and for development of a third primary melanoma for people who have two previous melanomas (bottom row).
Figure 2.
Figure 2.
Nomogram for estimating predicted 1-year, 5-year and 10-year risk of developing a second primary melanoma, for people who have one previous primary melanoma. To calculate an individual’s risk, sum the points (top row) that correspond to each of the individual’s risk factors, then find the 1-year, 5-year and 10-year absolute risks that correspond with the total points (bottom rows). The 12 factors are: age at first melanoma, sex, previous keratinocyte cancer, family history of melanoma in first degree relatives, skin colour, ability to tan, naevus density (none, few, some, many), polygenic risk score, CDKN2A functional mutation status, recreational sun exposure in beach and water activities from age 15 (average hours/day), anatomical site and histological subtype of the previous primary melanoma. Refer to Table 2 of the main paper, and the Supplementary online material for more details of the variables.
Figure 3:
Figure 3:
Kaplan-Meier curves showing the proportion of patients within each quintile of risk from the prediction model who developed a subsequent melanoma during the follow-up period, for people with one previous melanoma (left), two previous melanomas (middle) or three previous melanomas (right).

Comment in

References

    1. van der Leest RJ, Flohil SC, Arends LR et al. Risk of subsequent cutaneous malignancy in patients with prior melanoma: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2015; 29:1053–62. - PubMed
    1. Gershenwald JE, Scolyer RA, Hess KR et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67:472–92. - PMC - PubMed
    1. Watts CG, Cust AE, Menzies SW et al. Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma. J Clin Oncol 2017; 35:63–71. - PubMed
    1. Watts CG, Dieng M, Morton RL et al. Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. Br J Dermatol 2015; 172:33–47. - PubMed
    1. Begg CB, Hummer AJ, Mujumdar U et al. A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int J Epidemiol 2006; 35:756–64. - PubMed

Publication types